Meaningful machine learning models and machine-learned pharmacophores
  from fragment screening campaigns
  Machine learning (ML) is widely used in drug discovery to train models that
predict protein-ligand binding. These models are of great value to medicinal
chemists, in particular if they provide case-specific insight into the physical
interactions that drive the binding process. In this study we derive ML models
from over 50 fragment-screening campaigns to introduce two important elements
that we believe are absent in most -- if not all -- ML studies of this type
reported to date: First, alongside the observed hits we use to train our
models, we incorporate true misses and show that these experimentally validated
negative data are of significant importance to the quality of the derived
models. Second, we provide a physically interpretable and verifiable
representation of what the ML model considers important for successful binding.
This representation is derived from a straightforward attribution procedure
that explains the prediction in terms of the (inter-)action of chemical
environments. Critically, we validate the attribution outcome on a large scale
against prior annotations made independently by expert molecular modellers. We
find good agreement between the key molecular substructures proposed by the ML
model and those assigned manually, even when the model's performance in
discriminating hits from misses is far from perfect. By projecting the
attribution onto predefined interaction prototypes (pharmacophores), we show
that ML allows us to formulate simple rules for what drives fragment binding
against a target automatically from screening data.
